LCTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LCTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Lineage Cell Therapeutics's annualized net income for the quarter that ended in Mar. 2024 was $-26.17 Mil. Lineage Cell Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $10.69 Mil. Therefore, Lineage Cell Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -244.85%.
The historical rank and industry rank for Lineage Cell Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
During the past 13 years, Lineage Cell Therapeutics's highest Return-on-Tangible-Equity was 67.18%. The lowest was -194.82%. And the median was -40.98%.
The historical data trend for Lineage Cell Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Return-on-Tangible-Equity | Get a 7-Day Free Trial | -16.18 | -44.63 | -117.50 | -103.64 | -193.92 |
Lineage Cell Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Return-on-Tangible-Equity | Get a 7-Day Free Trial | -120.22 | -146.85 | -216.94 | -224.23 | -244.85 |
For the Biotechnology subindustry, Lineage Cell Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Return-on-Tangible-Equity falls into.
Lineage Cell Therapeutics's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -21.486 | / | ( (15.975 | + | 6.185 ) | / 2 ) | |
= | -21.486 | / | 11.08 | ||||
= | -193.92 % |
Lineage Cell Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -26.168 | / | ( (6.185 | + | 15.19) | / 2 ) | |
= | -26.168 | / | 10.6875 | ||||
= | -244.85 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.
Lineage Cell Therapeutics (AMEX:LCTX) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Anula Jayasuriya | director | 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022 |
Jill Ann Howe | officer: Chief Financial Officer | C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121 |
Dipti Amin | director | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Brian M Culley | director, officer: President and CEO | 6725 MESA RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121 |
Broadwood Partners Lp | 10 percent owner | BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019 |
Michael H. Mulroy | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Gary S. Hogge | officer: SVP,Clinical & Medical Affairs | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Samuel George A. Iii | officer: General Counsel/Secretary | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Angus C. Russell | director | C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Kevin Leon Cook | officer: Chief Financial Officer | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Alexandra Hernandez | officer: Sr Director Finance/Controller | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Brandi Roberts | officer: CFO & SVP, Finance | 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130 |
Chase C. Leavitt | officer: General Counsel/Secretary | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Edward Wirth | officer: Chief Medical Officer | C/O INVIVO THERAPEUTICS HOLDING CORP., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Don M Bailey | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92607 |
From GuruFocus
By Marketwired Marketwired • 01-04-2019
By PRNewswire PRNewswire • 06-01-2021
By Marketwired Marketwired • 02-26-2019
By PRNewswire PRNewswire • 07-04-2022
By PRNewswire PRNewswire • 07-14-2022
By Marketwired Marketwired • 01-30-2019
By Marketwired Marketwired • 02-14-2019
By PRNewswire PRNewswire • 06-14-2022
By PRNewswire PRNewswire • 04-20-2021
By PRNewswire PRNewswire • 06-24-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.